In a bold move, Coherus BioSciences, Inc. (Nasdaq: CHRS), headquartered in the heart of REDWOOD CITY, California, has set the stage for an exciting future. On September 22, 2023, this biotech trailblazer announced a game-changing development: the granting of stock options to six exceptional new team members.
Effective September 20, 2023, the compensation committee of Coherus BioSciences’ board of directors bestowed the power to purchase a total of 109,000 shares of the company’s common stock upon these rising stars. With a per-share exercise price set at $4.51, mirroring the closing trading price on the grant date, this strategic move underlines Coherus’ commitment to attracting and retaining top talent.
These coveted stock options, awarded under the aegis of the Coherus BioSciences, Inc. 2016 Employment Commencement Incentive Plan, embody a forward-looking strategy that was greenlit by the company’s board of directors back in June 2016. Operating under the auspices of Rule 5635(c)(4) of the Nasdaq Global Select Market, this initiative has successfully enticed the brightest minds in the industry to join forces with Coherus, heralding a new era of innovation and progress.